Economic evaluation of Avonex® (interferon beta-1a) in patients following a single demyelinating event

Abstract

Background: Interferon beta-1a (Avonex®)30 mg, intramuscular (i.m.), once weekly is efficacious in delaying clinically definite multiple sclerosis (CDMS) following a single demyelinating event (SDE). This study determined the cost effectiveness of Avonex® compared to current treatment in delaying the onset of CDMS. Methods: A cost-effectiveness analysis (CEA) and cost-utility analysis (CUA) were performed from Ministry of Health (MoH) and societal perspectives. For CEA, the outcome of interest was time spent in the pre-CDMS state, termed monosymptomatic life years (MLY) gained. For CUA, the outcome was quality-adjusted monosymptomatic life years (QAMLY) gained. A Markov model was developed with transitional probabilities and utilities derived from the literature. Costs were reported in 2002 Canadian dollars. Costs and outcomes were discounted at 5%. The time horizon was 12 years for the CEA, and 15 years for the CUA. All uncertainties were tested via univariate and multivariate sensitivity analyses. Results: In the CEA, the incremental cost of Avonex® per MLY gained was $53 110 and $44 789 from MoH and societal perspectives, respectively. In the CUA, the incremental cost of Avonex® per QAMLY gained was $227 586 and $189 286 from MoH and societal perspectives, respectively. Both models were sensitive to the probability of progressing to CDMS and the analytical time horizon. The CUA was sensitive to the utilities value. Conclusion: Avonex® may be considered as a reasonably cost-effective approach to treatment of patients experiencing an SDE. In addition, the overall incremental cost-effectiveness profile of Avonex® improves if treatment is initiated in pre-CDMS rather than waiting until CDMS.

Keywords

Canada cost effectiveness economic interferon beta-1a multiple sclerosis single demyelinating event

Get full access to this article

View all access options for this article.

References

Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

McDonald WI , Compston A , Edan G , Goodkin D , Hartung HP , Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis . Ann Neurol 2001; 50: 121-127 .

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis . N Engl J Med 2000; 343: 898-904 .

Fazekas F , Barkhof F , Filippi M , Grossman RI , Li DKB , McDonald WI et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis . Neurology 1999; 53: 448-456 .

Optic Neuritis Study Group . The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial . Neurology 1997; 49: 1404-1413 .

Morrissey SP , Miller DH , Kendall BE , Kingsley DP , Kelly MA , Francis DA et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study . Brain 1993; 116: 135-146 .

O’Riordan JI , Thompson AJ , Kingsley DP , MacManus DG , Kendall BE , Rudge P et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up . Brain 1998; 121: 495-503 .

Rudick RA , Goodkin DE eds. Treatment of multiple sclerosis: trial design, results, and future perspectives. New York: Springer Verlag , 1992: 49-51.

The Canadian Burden of Illness Study Group . Burden of illness of multiple sclerosis. Part I: cost of illness . Can J Neurol Sci 1998; 25: 23-30 .

10.

Grima DT , Torrance GW , Francis G , Rice GP , Rosner AJ , Lafortune L. Cost and health related quality of life consequences of multiple sclerosis . Mult Scler 2000; 6: 91-98 .

11.

Kobelt G , Jonsson L , Miltenburger C , Jonsson B. Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease date . Int J Technol Assess Health Care 2002; 18: 127-138 .

12.

Nuijten MJC , Hutton J. Cost-effectiveness analysis of inter-feron beta in multiple sclerosis: a Markov process analysis . Value Health 2002; 5: 44-54 .

13.

Henriksson F , Fredrikson S , Masterman T , Jönsson B. Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden . Eur J Neurol 2001; 8: 27-35 .

14.

The Canadian Burden of Illness Study Group . Burden of illness of multiple sclerosis. Part II: quality of life . Can J Neurol Sci 1998; 25: 31-38 .

15.

Parkin D , Jacoby A , McNamee P , Miller P , Thomas S , Bates D. Treatment of multiple sclerosis with interferon B: and appraisal of cost-effectiveness and quality of life . J Neurol Neurosurg Psychiatry 2000; 68: 144-149 .

16.

Canadian Coordinating Office for Health Technology Assessment . Guidelines for economic evaluation of pharmaceuticals: Canada, second edition. Ottawa, ON: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) , 1997.

17.

Weinshenker BG , Bass B , Rice GP , Noseworthy J , Carriere W , Baskerville J et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability . Brain 1989; 112: 133-146 .

18.

EuroQol Group . EuroQol: a new facility for the measurement of health related quality of life . Health Policy 1990; 16: 208-208 .

19.

Ministry of Health . Ontario Drug Benefit Formulary Comparative Drug Index. Toronto, ON: Queen’s Printer for Ontario , 2001.

20.

Ontario Ministry of Health . Schedule of Benefits; Physician Services under the Health Insurance Act. Toronto, ON: Institutional Services Branch, Ministry of Health , 1993.

21.

Ontario Ministry of Health . Schedule of Benefits: Laboratory services under the Health Insurance Act. Toronto, ON: Institutional Services Branch, Ministry of Health , 1993.

22.

Ontario Ministry of Health. Ontario Case Costing Initiative: Case Mix Groups for 2001. Retrieved 5 November 2002, from: http://www.occp.com/data_analysis/fy98_99_00/FY0001forplex01.xls.

23.

Statistics Canada . Employment, earnings and hours . The Daily, April 27, 2001. Retrieved 1 August 2003, from: http://www.statcan.ca/Daily/English/010427/d010427a.htm.

24.

Sculpher M. The role and estimation of productivity costs in economic evaluation. In Drummond MF , McGuire A eds. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press , 2001: 94-112.

25.

Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. Internal Study Report, Biogen, 2000: Tables 16.2.6.1 and 16.2.6.2.

26.

Briggs AH. Handling uncertainty in economic evaluation and presenting the results. In Drummond MF , Alistair M eds. Economic evaluation in health care, Oxford: Oxford University Press , 2001: 172-214.